FX.co ★ Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Platform Assets

Ginkgo Bioworks, operating under the stock symbol DNA, recently made public its purchase of assets from Modulus Therapeutics' cell therapy platform. This includes Modulus' libraries of switch receptors and chimeric antigen receptors. Modulus Therapeutics, which specializes in cell engineering, designs innovative cell therapies aimed at combating autoimmune diseases. A particular focus for them are context-responsive CAR-NK cells that are specially designed to draw from the autoimmune microenvironment to enhance safety and efficacy.

Ginkgo Bioworks has stated that the assets it has acquired from Modulus will enhance its own cell therapy capabilities. As the company looks to the future post-acquisition, it aims to support its clients who are working on improving the effectiveness of CAR therapies based on NK-cell and T-cell.

For more health-related news, feel free to check out rttnews.com.